LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 2 | G06 | 72 | hr | 1401 | 1257 | 4223 | 0.2977 | -0.0512 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 3 | G06 | 72 | hr | 1401 | 1032 | 4223 | 0.2444 | -0.1310 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 1 | P18 | 72 | hr | 1401 | 3805 | 4223 | 0.9010 | 0.8518 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 2 | P18 | 72 | hr | 1401 | 4017 | 4223 | 0.9512 | 0.9270 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 3 | P18 | 72 | hr | 1401 | 3368 | 4223 | 0.7975 | 0.6969 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 1 | A12 | 72 | hr | 1401 | 3954 | 4223 | 0.9363 | 0.9046 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 2 | A12 | 72 | hr | 1401 | 3475 | 4223 | 0.8229 | 0.7349 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 3 | A12 | 72 | hr | 1401 | 3448 | 4223 | 0.8165 | 0.7253 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1401 | 5290 | 4223 | 1.2526 | 1.3781 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1401 | 4625 | 4223 | 1.0952 | 1.1424 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1401 | 4675 | 4223 | 1.1070 | 1.1602 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 1 | A24 | 72 | hr | 1401 | 3584 | 4223 | 0.8487 | 0.7735 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 2 | A24 | 72 | hr | 1401 | 3743 | 4223 | 0.8863 | 0.8299 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 1401 | 3857 | 4223 | 0.9133 | 0.8703 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 1 | P12 | 72 | hr | 1401 | 3888 | 4223 | 0.9207 | 0.8812 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 2 | P12 | 72 | hr | 1401 | 4190 | 4223 | 0.9922 | 0.9883 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 3 | P12 | 72 | hr | 1401 | 4415 | 4223 | 1.0454 | 1.0680 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 1 | D06 | 72 | hr | 1401 | 4257 | 4223 | 1.0080 | 1.0120 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 2 | D06 | 72 | hr | 1401 | 4675 | 4223 | 1.1070 | 1.1602 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 3 | D06 | 72 | hr | 1401 | 4337 | 4223 | 1.0270 | 1.0404 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 1 | I06 | 72 | hr | 1401 | 3732 | 4223 | 0.8837 | 0.8260 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 2 | I06 | 72 | hr | 1401 | 4122 | 4223 | 0.9761 | 0.9642 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 3 | I06 | 72 | hr | 1401 | 3545 | 4223 | 0.8394 | 0.7597 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 1401 | 3605 | 4223 | 0.8536 | 0.7809 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 1401 | 3821 | 4223 | 0.9048 | 0.8575 |